Compare AbbVie Inc (ABBV) vs IAC/Interactivecorp (PPLI) Price & Performance

AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).

Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.

PPLI trades at $47.62, up 1.86% today, showing bullish technical momentum with moving averages supporting the uptrend. However, the stock has missed earnings expectations for three consecutive quarters, with Q1 2026 EPS of -$0.94 falling short of the -$0.37 estimate. Despite a high gross margin of 66.49%, net income margin remains thin at 1.75%, and cash flow turned negative in 2025 with a net outflow of $820.42 million. Analyst consensus remains positive with a $55.40 price target, though recent news questions valuation after a rally.

The outlook is mixed: strong analyst buy ratings and a discounted P/B of 0.77 suggest upside potential, but persistent earnings misses and negative cash flow pose significant risks. Revenue decline from $5.2B in 2022 to $2.4B in 2025 highlights operational challenges. Investors should weigh the bullish technical setup against fundamental weaknesses and high debt levels before committing capital.